UK’s NICE backs Roche drug as maintenance therapy (Reuters)
Reuters – Roche’s cancer drug MabThera has been recommended for use on Britain’s state health service as a maintenance therapy for patients with follicular non-Hodgkin’s lymphoma, expanding the market for the medicine.
View full post on Yahoo! News: Health News
Leave a Reply